注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Adaptimmune Therapeutics PLC是一家临床阶段的生物制药公司。该公司专注于为癌症患者提供细胞疗法。它为实体瘤开发 T 细胞疗法,并报告了七种实体瘤适应症的临床反应(根据 RECIST 1.1)。它的平台能够识别癌症靶点,发现和开发对这些靶点有活性的细胞治疗候选物,并产生用于患者的治疗候选物。其候选细胞疗法包括使用基因工程T细胞受体的特异性肽增强亲和力受体(SPEAR)T细胞;肿瘤浸润淋巴细胞(TiL),其中患者自身的T细胞与其下一代技术共同给药,以及HLA非依赖性TCR(HiT),其中表面蛋白的靶向独立于肽-HLA复合物。其临床试验包括使用afamitres基因autoleucel的Spearhead-1 II期试验;通过ADP-A2M4CD8等的I期试验。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Lawrence M. Alleva | 71 | 2015 | Independent Non-Executive Director |
Adrian G. Rawcliffe | 49 | 2015 | CEO, Principal Accounting Officer & Director |
David M. Mott | 56 | 2015 | Independent Chairman of the Board of Directors |
Wolf H. Fridman | - | - | Member of the Scientific Advisory Board |
Ali Behbahani | 47 | 2015 | Independent Non-Executive Director |
Andy Sewell | - | - | Member of the Scientific Advisory Board |
Stephan A. Grupp | - | - | Member of the Scientific Advisory Board |
Mario Sznol | - | - | Member of the Scientific Advisory Board |
Kristen M. Hege | 60 | 2023 | Independent Non-Executive Director |
Wolf Herve Fridman | - | - | Member of the Scientific Advisory Board |
Thomas Gajewski | - | - | Member of the Scientific Advisory Board |
Michael Dustin | - | - | Member of the Scientific Advisory Board |
Malcolm K. Brenner | 71 | - | Member of the Scientific Advisory Board |
Priti Hegde | 52 | 2023 | Independent Non-Executive Director |
Garry E. Menzel | 60 | 2023 | Independent Non-Executive Director |
Andrew R. Allen | 58 | 2023 | Independent Non-Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核